Yale Spinout Modifi Biosciences Nets $2.4M From NCI to Advance Targeted Cancer Drugs Toward Clinic
The firm is developing a pipeline of therapeutics directed at cancer tumors that have lost expression of the DNA repair protein MGMT.
Source: precisiononcologynews.com